Medicus Pharma (MDCX) Return on Equity (2024 - 2025)
Medicus Pharma (MDCX) posted Return on Equity of 0.39% for Q4 2025, up 407.6% quarter-over-quarter from 0.13% in Q3 2025, and up 42.0% year-on-year from 0.27% in Q4 2024.
Medicus Pharma (MDCX) Return on Equity (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Return on Equity for 2 consecutive years, with 0.39% the latest figure, recorded in Q4 2025.
- Return on Equity for Q4 2025 came in at 0.39%, up 42.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 0.39% (up 42.0% YoY), and the FY2025 annual result was 0.22%, down 17.0% from the prior year.
- Return on Equity was 0.39% for Q4 2025 at Medicus Pharma, up from 0.13% in the prior quarter.
- Over five years, Return on Equity peaked at 0.39% in Q4 2025 and troughed at 0.13% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 0.01% |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 0.00% |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -0.01% |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 0.00% |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 0.01% |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 0.00% |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 0.00% |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | 0.39% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.39% |
| Sep 30, 2025 | -0.13% |
| Jun 30, 2025 | -0.06% |
| Mar 31, 2025 | -0.06% |
| Dec 31, 2024 | -0.03% |
| Sep 30, 2024 | -0.01% |